BRIEF-Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051

Reuters02-18

BRIEF-Aprea <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051

Feb 18 (Reuters) - Aprea Therapeutics Inc APRE.O:

APREA THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE CLINICAL ACTIVITY FOR WEE1 INHIBITOR, APR-1051, INCLUDING SECOND PARTIAL RESPONSE IN ONGOING ACESOT-1051 TRIAL
APREA THERAPEUTICS INC - TUMOR SHRINKAGE OF 50% AND SIGNIFICANT CA-125 BIOMARKER REDUCTION OBSERVED AT 220 MG DOSE LEVEL
APREA THERAPEUTICS INC - UPDATE FROM TRIAL IS EXPECTED IN Q2 OF 2026

Source text: ID:nGNX9NWpJK

Further company coverage: APRE.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612494344?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 22:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612494344","market":"fut","top_or_hot":-1,"title":"BRIEF-Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aprea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051</title></head><body><p><span>Feb 18 (Reuters)</span><span> - </span>Aprea Therapeutics Inc <span>APRE.O</span>:</p><ul><li><p>APREA THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE CLINICAL ACTIVITY FOR WEE1 INHIBITOR, APR-1051, INCLUDING SECOND PARTIAL RESPONSE IN ONGOING ACESOT-1051 TRIAL</p></li><li><p>APREA THERAPEUTICS INC - TUMOR SHRINKAGE OF 50% AND SIGNIFICANT CA-125 BIOMARKER REDUCTION OBSERVED AT 220 MG DOSE LEVEL</p></li><li><p>APREA THERAPEUTICS INC - UPDATE FROM TRIAL IS EXPECTED IN <a href=\"https://laohu8.com/S/QTWO\">Q2</a> OF 2026</p></li></ul><p>Source text: <span>ID:nGNX9NWpJK</span></p><p>Further company coverage: <span>APRE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-18 22:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aprea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051</title></head><body><p><span>Feb 18 (Reuters)</span><span> - </span>Aprea Therapeutics Inc <span>APRE.O</span>:</p><ul><li><p>APREA THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE CLINICAL ACTIVITY FOR WEE1 INHIBITOR, APR-1051, INCLUDING SECOND PARTIAL RESPONSE IN ONGOING ACESOT-1051 TRIAL</p></li><li><p>APREA THERAPEUTICS INC - TUMOR SHRINKAGE OF 50% AND SIGNIFICANT CA-125 BIOMARKER REDUCTION OBSERVED AT 220 MG DOSE LEVEL</p></li><li><p>APREA THERAPEUTICS INC - UPDATE FROM TRIAL IS EXPECTED IN <a href=\"https://laohu8.com/S/QTWO\">Q2</a> OF 2026</p></li></ul><p>Source text: <span>ID:nGNX9NWpJK</span></p><p>Further company coverage: <span>APRE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APRE","symbol_name":"Aprea Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nTUA8ZCXM3:1","article_id":"2612494344","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612494344","pubTimestamp":1771423609,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051Feb 18 (Reuters) - Aprea Therapeutics Inc APRE.O:APREA THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE C","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APRE":"Aprea Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"简介-Aprea Therapeutics宣布Wee1抑制剂APR-1051的额外积极临床活性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APRE":0.9},"content_text":"BRIEF-Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051Feb 18 (Reuters) - Aprea Therapeutics Inc APRE.O:APREA THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE CLINICAL ACTIVITY FOR WEE1 INHIBITOR, APR-1051, INCLUDING SECOND PARTIAL RESPONSE IN ONGOING ACESOT-1051 TRIALAPREA THERAPEUTICS INC - TUMOR SHRINKAGE OF 50% AND SIGNIFICANT CA-125 BIOMARKER REDUCTION OBSERVED AT 220 MG DOSE LEVELAPREA THERAPEUTICS INC - UPDATE FROM TRIAL IS EXPECTED IN Q2 OF 2026Source text: ID:nGNX9NWpJKFurther company coverage: APRE.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612494344","isCrawlerRequest":true}